We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has ANI Pharmaceuticals (ANIP - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ANI Pharmaceuticals is a member of our Medical group, which includes 1010 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ANI Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ANIP's full-year earnings has moved 0.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ANIP has moved about 6.6% on a year-to-date basis. In comparison, Medical companies have returned an average of 4.4%. This means that ANI Pharmaceuticals is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Doximity (DOCS - Free Report) . The stock has returned 44.4% year-to-date.
The consensus estimate for Doximity's current year EPS has increased 13.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, ANI Pharmaceuticals is a member of the Medical - Biomedical and Genetics industry, which includes 510 individual companies and currently sits at #69 in the Zacks Industry Rank. Stocks in this group have gained about 12.6% so far this year, so ANIP is slightly underperforming its industry this group in terms of year-to-date returns.
Doximity, however, belongs to the Medical Services industry. Currently, this 59-stock industry is ranked #142. The industry has moved +4.3% so far this year.
Investors with an interest in Medical stocks should continue to track ANI Pharmaceuticals and Doximity. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has ANI Pharmaceuticals (ANIP - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ANI Pharmaceuticals is a member of our Medical group, which includes 1010 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ANI Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ANIP's full-year earnings has moved 0.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ANIP has moved about 6.6% on a year-to-date basis. In comparison, Medical companies have returned an average of 4.4%. This means that ANI Pharmaceuticals is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Doximity (DOCS - Free Report) . The stock has returned 44.4% year-to-date.
The consensus estimate for Doximity's current year EPS has increased 13.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, ANI Pharmaceuticals is a member of the Medical - Biomedical and Genetics industry, which includes 510 individual companies and currently sits at #69 in the Zacks Industry Rank. Stocks in this group have gained about 12.6% so far this year, so ANIP is slightly underperforming its industry this group in terms of year-to-date returns.
Doximity, however, belongs to the Medical Services industry. Currently, this 59-stock industry is ranked #142. The industry has moved +4.3% so far this year.
Investors with an interest in Medical stocks should continue to track ANI Pharmaceuticals and Doximity. These stocks will be looking to continue their solid performance.